Immunotherapy: Open Access

Immunotherapy: Open Access
Open Access

ISSN: 2471-9552

+44 1223 790975

Chunyi Li

College of Life Sciences, Shihezi University, Xinjiang, China

  • Commentary   
    Attention should be paid to the Adverse Reactions of PD-1/PD-L 1 Inhibitors
    Author(s): Peng Wu*, Shulan Lin, Jiao Jiao and Chunyi Li

    The adverse reactions caused by using programmed cell death-1/programmed cell death ligand-1(PD-1/PD-L1) inhibitors were evaluated. PD-1 is an immune checkpoint receptor which expresses and activates specific immune cells. When PD-1 binds to immune cells, it will make them useless against cancer cells. PD-1/PD-L1 inhibitor has been an emerging therapy recently and is widely used in cancer patients. PD-1/PD-L1 inhibitor may cause immune imbalance in common cancer patients and organ transplant cancer patients, which may lead to T cells attacking their own organs, causing some adverse reactions against patients, and even endangering their lives... View More»

    Abstract HTML PDF